ABIOMED (NASDAQ:ABMD) had its price objective hoisted by Jefferies Group to $250.00 in a report published on Friday morning, The Fly reports. They currently have a buy rating on the medical equipment provider’s stock.

ABMD has been the subject of several other research reports. Zacks Investment Research upgraded shares of ABIOMED from a hold rating to a buy rating and set a $220.00 price target for the company in a report on Tuesday, November 7th. BidaskClub upgraded shares of ABIOMED from a hold rating to a buy rating in a report on Thursday. Piper Jaffray Companies boosted their price target on shares of ABIOMED to $200.00 and gave the company an overweight rating in a report on Thursday, October 26th. BTIG Research restated a hold rating on shares of ABIOMED in a report on Sunday, October 29th. Finally, SunTrust Banks restated a buy rating and issued a $195.00 price target on shares of ABIOMED in a report on Wednesday, November 1st. Two research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. ABIOMED presently has a consensus rating of Buy and a consensus price target of $199.67.

ABIOMED (ABMD) traded up $4.96 during trading hours on Friday, hitting $215.11. 283,300 shares of the stock traded hands, compared to its average volume of 256,522. ABIOMED has a twelve month low of $103.53 and a twelve month high of $216.15. The company has a debt-to-equity ratio of 0.02, a quick ratio of 5.20 and a current ratio of 5.84. The company has a market cap of $9,510.00, a price-to-earnings ratio of 105.97, a P/E/G ratio of 2.84 and a beta of 0.15.

ABIOMED (NASDAQ:ABMD) last posted its quarterly earnings results on Thursday, October 26th. The medical equipment provider reported $0.54 EPS for the quarter, beating the consensus estimate of $0.38 by $0.16. ABIOMED had a net margin of 18.27% and a return on equity of 13.89%. The business had revenue of $132.80 million during the quarter, compared to analyst estimates of $131.18 million. During the same quarter in the previous year, the business posted $0.20 EPS. The company’s quarterly revenue was up 28.9% compared to the same quarter last year. sell-side analysts expect that ABIOMED will post 2.41 EPS for the current fiscal year.

In related news, VP Michael G. Howley sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, October 30th. The shares were sold at an average price of $178.64, for a total transaction of $1,786,400.00. Following the completion of the transaction, the vice president now owns 56,757 shares in the company, valued at approximately $10,139,070.48. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Dorothy E. Puhy sold 6,364 shares of the business’s stock in a transaction that occurred on Monday, October 30th. The stock was sold at an average price of $179.08, for a total transaction of $1,139,665.12. Following the transaction, the director now owns 39,532 shares of the company’s stock, valued at approximately $7,079,390.56. The disclosure for this sale can be found here. Insiders own 7.00% of the company’s stock.

Several hedge funds and other institutional investors have recently bought and sold shares of ABMD. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in ABIOMED by 15.0% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,511 shares of the medical equipment provider’s stock valued at $217,000 after purchasing an additional 197 shares in the last quarter. Bluestein R H & Co. increased its stake in ABIOMED by 7.5% during the 2nd quarter. Bluestein R H & Co. now owns 2,850 shares of the medical equipment provider’s stock valued at $408,000 after purchasing an additional 200 shares in the last quarter. Ameritas Investment Partners Inc. increased its stake in ABIOMED by 2.2% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 12,195 shares of the medical equipment provider’s stock valued at $1,748,000 after purchasing an additional 259 shares in the last quarter. Sterling Capital Management LLC increased its stake in ABIOMED by 2.2% during the 3rd quarter. Sterling Capital Management LLC now owns 13,139 shares of the medical equipment provider’s stock valued at $2,215,000 after purchasing an additional 281 shares in the last quarter. Finally, State of Wisconsin Investment Board increased its stake in ABIOMED by 3.6% during the 3rd quarter. State of Wisconsin Investment Board now owns 8,364 shares of the medical equipment provider’s stock valued at $1,410,000 after purchasing an additional 294 shares in the last quarter. Hedge funds and other institutional investors own 90.75% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “ABIOMED (ABMD) PT Raised to $250.00” was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of international copyright & trademark laws. The correct version of this piece of content can be accessed at https://www.thecerbatgem.com/2018/01/15/abiomed-abmd-pt-raised-to-250-00.html.

About ABIOMED

ABIOMED, Inc is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company operates in the segment of the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Company develops, manufactures and markets products that are designed to enable the heart to rest, heal and recover by improving blood flow to the coronary arteries and end-organs and/or temporarily performing the pumping function of the heart.

The Fly

Analyst Recommendations for ABIOMED (NASDAQ:ABMD)

Receive News & Ratings for ABIOMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED and related companies with MarketBeat.com's FREE daily email newsletter.